FDA Releases New Draft Guidance on DSCSA Tracking Standards, Definitions

Drug GMP Report
The FDA issued two draft guidances aimed at implementing the Drug Supply Chain Security Act’s provisions for an electronic track-and-trace system for certain prescription drugs extending throughout the supply chain — one recommending data and documentation practices and another defining terms such as “suspect products” and “illegitimate products.”

To View This Article:


Subscribe To Drug GMP Report